Using Drosophila models of neurodegenerative diseases for drug discovery

Bibliography

• Terry RD. Structural basis of the cognitive alterations in Alzheimer's disease. In: Terry RD, editor, Alzheimer disease. Raven, New York; 1994
   Google Scholar
• Auluck PK, Bonini NM. Pharmacological prevention of Parkinson disease in Drosophila. Nat Med 2002;8(11):1185-6
   PubMed Web of Science ®Google Scholar
• Harvey BK, Richie CT, Hoffer BJ, Airavaara M. Transgenic animal models of neurodegeneration based on human genetic studies. J Neural Transm 2010. [Epub ahead of print]
   Google Scholar
• Mudher A, Newman TA. Drosophila: a toolbox for the study of neurodegenerative disease. Taylor & Francis, New York, Abingdon; 2008
   Google Scholar
• Greenspan RJ. Fly pushing: the theory and practice of Drosophila genetics. 2nd edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; 2004
   Google Scholar
• Sheeba V. The Drosophila melanogaster circadian pacemaker circuit. J Genet 2008;87(5):485-93
   PubMed Web of Science ®Google Scholar
• Keene AC, Waddell S. Drosophila olfactory memory: single genes to complex neural circuits. Nat Rev Neurosci 2007;8(5):341-54
   PubMed Web of Science ®Google Scholar
• Lawrence PA. The making of a fly: the genetics of animal design. Blackwell Scientific, Oxford; 1992
   Google Scholar
• Paaby AB, Schmidt PS. Dissecting the genetics of longevity in Drosophila melanogaster. Fly (Austin) 2009;3(1):29-38
   PubMed Web of Science ®Google Scholar
• Duffy JB. GAL4 system in Drosophila: a fly geneticist's Swiss army knife. Genesis 2002;34(1-2):1-15
   PubMed Web of Science ®Google Scholar
• Reiter LT, Potocki L, Chien S, A systematic analysis of human disease-associated gene sequences in Drosophila melanogaster. Genome Res 2001;11(6):1114-25
   PubMed Web of Science ®Google Scholar
• Budnik V. Neuromuscular Junctions in Drosophila. Elsevier Science & Technology Books, London, UK; 1999
   Google Scholar
• Mudher A, Shepherd D, Newman TA, GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol Psychiatry 2004;9(5):522-30
   PubMed Web of Science ®Google Scholar
• Sinadinos C, Burbidge-King T, Soh D, Live axonal transport disruption by mutant huntingtin fragments in Drosophila motor neuron axons. Neurobiol Dis 2009;34(2):389-95
   PubMed Web of Science ®Google Scholar
• Gunawardena S, Her LS, Brusch RG, Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 2003;40(1):25-40
   PubMed Web of Science ®Google Scholar
• Feany MB, Bender WW. A Drosophila model of Parkinson's disease. Nature 2000;404(6776):394-8
   PubMed Web of Science ®Google Scholar
• Feany MB. ASIP outstanding investigator award lecture. New approaches to the pathology and genetics of neurodegeneration. Am J Pathol 2010;176(5):2058-66
   PubMedGoogle Scholar
• Bilen J, Bonini NM. Drosophila as a model for human neurodegenerative disease. Annu Rev Genet 2005;39:153-71
   PubMed Web of Science ®Google Scholar
• Vidal M, Cagan RL. Drosophila models for cancer research. Curr Opin Genet Dev 2006;16(1):10-16
   PubMed Web of Science ®Google Scholar
• Devineni AV, Heberlein U. Preferential ethanol consumption in Drosophila models features of addiction. Curr Biol 2009;19(24):2126-32
   PubMed Web of Science ®Google Scholar
• Jackson GR, Salecker I, Dong X, Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. Neuron 1998;21(3):633-42
   PubMed Web of Science ®Google Scholar
• Williams DW, Tyrer M, Shepherd D. Tau and tau reporters disrupt central projections of sensory neurons in Drosophila. J Comp Neurol 2000;428(4):630-40
   PubMed Web of Science ®Google Scholar
• Chee FC, Mudher A, Cuttle MF, Over-expression of tau results in defective synaptic transmission in Drosophila neuromuscular junctions. Neurobiol Dis 2005;20(3):918-28
   PubMed Web of Science ®Google Scholar
• Jackson GR, Wiedau-Pazos M, Sang TK, Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 2002;34(4):509-19
   PubMed Web of Science ®Google Scholar
• Park J, Kim Y, Chung J. Mitochondrial dysfunction and Parkinson's disease genes: insights from Drosophila. Dis Model Mech 2009;2(7-8):336-40
   PubMed Web of Science ®Google Scholar
• Iijima-Ando K, Iijima K. Transgenic Drosophila models of Alzheimer's disease and tauopathies. Brain Struct Funct 2010;214(2-3):245-62
   PubMed Web of Science ®Google Scholar
• Lu B, Vogel H. Drosophila models of neurodegenerative diseases. Annu Rev Pathol 2009;4:315-42
   PubMed Web of Science ®Google Scholar
• Min KT, Benzer S. Preventing neurodegeneration in the Drosophila mutant bubblegum. Science 1999;284(5422):1985-8
   PubMed Web of Science ®Google Scholar
• Steffan JS, Bodai L, Pallos J, Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001;413(6857):739-43
   PubMed Web of Science ®Google Scholar
• Steffan JS, Thompson LM. Targeting aggregation in the development of therapeutics for the treatment of Huntington's disease and other polyglutamine repeat diseases. Expert Opin Ther Targets 2003;7(2):201-13
   PubMed Web of Science ®Google Scholar
• Pallos J, Bodai L, Lukacsovich T, Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum Mol Genet 2008;17(23):3767-75
   PubMed Web of Science ®Google Scholar
• Thomas EA, Coppola G, Desplats PA, The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc Natl Acad Sci USA 2008;105(40):15564-9
   PubMed Web of Science ®Google Scholar
• Kontopoulos E, Parvin JD, Feany MB. Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet 2006;15(20):3012-23
   PubMed Web of Science ®Google Scholar
• Cowan CM, Chee F, Shepherd D, Mudher A. Disruption of neuronal function by soluble hyperphosphorylated tau in a Drosophila model of tauopathy. Biochem Soc Trans 2010;38(2):564-70
   PubMedGoogle Scholar
• Cowan CM, Bossing T, Page A, Soluble hyper-phosphorylated tau causes microtubule breakdown and functionally compromises normal tau in vivo. Acta Neuropathol 2010 120(5):593-604
   PubMed Web of Science ®Google Scholar
• Whitworth AJ, Wes PD, Pallanck LJ. Drosophila models pioneer a new approach to drug discovery for Parkinson's disease. Drug Discov Today 2006;11(3-4):119-26
   PubMed Web of Science ®Google Scholar
• Jia H, Li X, Gao H, High doses of nicotinamide prevent oxidative mitochondrial dysfunction in a cellular model and improve motor deficit in a Drosophila model of Parkinson's disease. J Neurosci Res 2008;86(9):2083-90
   PubMed Web of Science ®Google Scholar
• Wang D, Qian L, Xiong H, Antioxidants protect PINK1-dependent dopaminergic neurons in Drosophila. Proc Natl Acad Sci USA 2006;103(36):13520-5
   PubMed Web of Science ®Google Scholar
• Faust K, Gehrke S, Yang Y, Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease. BMC Neurosci 2009;10:109
   PubMed Web of Science ®Google Scholar
• Dias-Santagata D, Fulga TA, Duttaroy A, Feany MB. Oxidative stress mediates tau-induced neurodegeneration in Drosophila. J Clin Invest 2007;117(1):236-45
   PubMed Web of Science ®Google Scholar
• Rival T, Page RM, Chandraratna DS, Fenton chemistry and oxidative stress mediate the toxicity of the beta-amyloid peptide in a Drosophila model of Alzheimer's disease. Eur J Neurosci 2009;29(7):1335-47
   PubMed Web of Science ®Google Scholar
• Fujikake N, Nagai Y, Popiel HA, Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones. J Biol Chem 2008;283(38):26188-97
   PubMed Web of Science ®Google Scholar
• Wacker JL, Huang SY, Steele AD, Loss of Hsp70 exacerbates pathogenesis but not levels of fibrillar aggregates in a mouse model of Huntington's disease. J Neurosci 2009;29(28):9104-14
   PubMed Web of Science ®Google Scholar
• Ravikumar B, Vacher C, Berger Z, Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004;36(6):585-95
   PubMed Web of Science ®Google Scholar
• Berger Z, Ravikumar B, Menzies FM, Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet 2006;15(3):433-42
   PubMed Web of Science ®Google Scholar
• Sarkar S, Krishna G, Imarisio S, A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Hum Mol Genet 2008;17(2):170-8
   PubMed Web of Science ®Google Scholar
• Ehrnhoefer DE, Duennwald M, Markovic P, Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. Hum Mol Genet 2006;15(18):2743-51
   PubMed Web of Science ®Google Scholar
• Apostol BL, Kazantsev A, Raffioni S, A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proc Natl Acad Sci USA 2003;100(10):5950-5
   PubMed Web of Science ®Google Scholar
• Crowther DC, Kinghorn KJ, Miranda E, Intraneuronal Abeta, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer's disease. Neuroscience 2005;132(1):123-35
   PubMed Web of Science ®Google Scholar
• Outeiro TF, Kontopoulos E, Altmann SM, Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 2007;317(5837):516-19
   PubMed Web of Science ®Google Scholar
• Mahoney MB, Diggins L, Foos M, Modelling Alzheimer's disease in Drosophila melanogaster for large-scale compound screening. ICAD. Hawaii 2010
   Google Scholar
• Zhang X, Smith DL, Meriin AB, A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc Natl Acad Sci USA 2005;102(3):892-7
   PubMed Web of Science ®Google Scholar
• Chopra V, Fox JH, Lieberman G, A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse. Proc Natl Acad Sci USA 2007;104(42):16685-9
   PubMed Web of Science ®Google Scholar
• Desai UA, Pallos J, Ma AA, Biologically active molecules that reduce polyglutamine aggregation and toxicity. Hum Mol Genet 2006;15(13):2114-24
   PubMed Web of Science ®Google Scholar
• Cao W, Song HJ, Gangi T, Identification of novel genes that modify phenotypes induced by Alzheimer's beta-amyloid overexpression in Drosophila. Genetics 2008;178(3):1457-71
   PubMed Web of Science ®Google Scholar
• Tan L, Schedl P, Song HJ, The Toll – NFkappaB signaling pathway mediates the neuropathological effects of the human Alzheimer's Abeta42 polypeptide in Drosophila. PLoS One 2008;3(12):e3966
   PubMedGoogle Scholar
• Blard O, Feuillette S, Bou J, Cytoskeleton proteins are modulators of mutant tau-induced neurodegeneration in Drosophila. Hum Mol Genet 2007;16(5):555-66
   PubMed Web of Science ®Google Scholar
• Shulman JM, Feany MB. Genetic modifiers of tauopathy in Drosophila. Genetics 2003;165(3):1233-42
   PubMed Web of Science ®Google Scholar
• Fernandez-Funez P, Nino-Rosales ML, de Gouyon B, Identification of genes that modify ataxin-1-induced neurodegeneration. Nature 2000;408(6808):101-6
   PubMed Web of Science ®Google Scholar
• Ghosh S, Feany MB. Comparison of pathways controlling toxicity in the eye and brain in Drosophila models of human neurodegenerative diseases. Hum Mol Genet 2004;13(18):2011-18
   PubMed Web of Science ®Google Scholar
• Kazemi-Esfarjani P, Benzer S. Genetic suppression of polyglutamine toxicity in Drosophila. Science 2000;287(5459):1837-40
   PubMed Web of Science ®Google Scholar
• Greene JC, Whitworth AJ, Andrews LA, Genetic and genomic studies of Drosophila parkin mutants implicate oxidative stress and innate immune responses in pathogenesis. Hum Mol Genet 2005;14(6):799-811
   PubMed Web of Science ®Google Scholar
• Shulman JM, Shulman LM, Weiner WJ, Feany MB. From fruit fly to bedside: translating lessons from Drosophila models of neurodegenerative disease. Curr Opin Neurol 2003;16(4):443-9
   PubMed Web of Science ®Google Scholar
• Steinhilb ML, Dias-Santagata D, Fulga TA, Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. Mol Biol Cell 2007;18(12):5060-8
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Sang TK, Lawless GM, Jackson GR. Dissociation of tau toxicity and phosphorylation: role of GSK-3beta, MARK and Cdk5 in a Drosophila model. Hum Mol Genet 2009;18(1):164-77
   PubMed Web of Science ®Google Scholar
• Coulom H, Birman S. Chronic exposure to rotenone models sporadic Parkinson's disease in Drosophila melanogaster. J Neurosci 2004;24(48):10993-8
   PubMed Web of Science ®Google Scholar
• Botella JA, Bayersdorfer F, Gmeiner F, Schneuwly S. Modelling Parkinson's disease in Drosophila. Neuromolecular Med 2009;11(4):268-80
   PubMed Web of Science ®Google Scholar
• Rosato E, Kyriacou CP. Sleep, arousal, and rhythms in flies. Proc Natl Acad Sci USA 2008;105(50):19567-8
   PubMed Web of Science ®Google Scholar
• Mershin A, Pavlopoulos E, Fitch O, Learning and memory deficits upon TAU accumulation in Drosophila mushroom body neurons. Learn Mem 2004;11(3):277-87
   PubMed Web of Science ®Google Scholar
• Ferveur JF. Drosophila female courtship and mating behaviors: sensory signals, genes, neural structures and evolution. Curr Opin Neurobiol 2010. [Epub ahead of print]
   Google Scholar
• Avanesian A, Semnani S, Jafari M. Can Drosophila melanogaster represent a model system for the detection of reproductive adverse drug reactions? Drug Discov Today 2009;14(15-16):761-6
   PubMed Web of Science ®Google Scholar